Taclonex Granted New Indication for Scalp Plaque Psoriasis in Adolescent Patients

September 30, 2014

LEO Pharma Inc., has received a new indication for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years. The new indication represents the first indication for adolescent patients aged 12 years and older with scalp plaque psoriasis on the market. Taclonex® Topical Suspension is a first-line, once-daily combination product indicated for treatment of both scalp and body plaque psoriasis in adults age 18 and above for up to eight weeks, and now for the treatment of plaque psoriasis of the scalp in pediatric patients 12 to 17 years for the same period.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free